MG01-T521 is under clinical development by Inmunotek and currently in Phase III for Allergic Rhino-Conjunctivitis. According to GlobalData, Phase III drugs for Allergic Rhino-Conjunctivitis have a 21% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how MG01-T521’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MG01-T521 overview

MG01-T521 is under development for the treatment of allergic rhinitis, allergic rhinoconjunctivitis and allergic asthma due to grass and Cupressaceae pollen. It is administered through subcutaneous route. It comprises of purified and polymerized with glutaraldehyde allergen extract, from a mixture of grasses (Phleum pratense, Holcus lanatus, Poa pratensis, Festuca pratensis, Lolium perenne and Dactylis glomerata) and cupresaceae (Juniperus oxycedrus), adsorbed on aluminum hydroxide.

Inmunotek overview

Inmunotek opearates as a pharmaceutical company. It develops, produces and markets products for allergy and other immune-based diseases and manufactures veterinary medicine. It also produces raw materials such as biological products, including fungi, bacteria and mites.

For a complete picture of MG01-T521’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.